Federal Register notice: FDA announces the renewal of its Science Board for an additional two years.
Troutman Pepper attorneys explain the potential benefits in FDAs new Emerging Drug Safety Technology Program.
FDA plans to ask its Vaccines and Related Biological Products Advisory Committee to discuss potential safety concerns related to pediatric respiratory...
The National Institutes of Health ends a trial of an mpox antiviral drug that failed to produce an efficacy signal.
Johnson & Johnson reports data from its Phase 3 CARTITUDE-4 study that show Carvykti significantly increased minimal residual disease (MRD) negativity...
Two men are convicted of securities fraud in a case involving misrepresented submissions to FDA for a drug purportedly intended to treat HIV and Covid...
FDA warns Chinas Guangzhou Four Es Scientific Co. about CGMP violations in its production of finished drugs.
